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1. Introduction 
Ectopic pregnancy (EP) accounts for approximately 75% of deaths in the first trimester, and 
9% of all pregnancy-related deaths are the result of EP. 
Recently, EP can be diagnosed accurately at a very early stage using transvaginal ultrasound 
and serum hCG measurement (1). Methtorexate (MTX) is in a class of drugs known as folic 
acid antagonists, and folic acid is an essential component in the synthesis of DNA 
precursors such as purines and thymidylate. MTX was originally used to treat cancer, 
trophoblastic disease, psoriasis, and rheumatoid arthritis; however, since 1982,  it has been 
used to successfully treat EP (2). Treatment with MTX now reportedly achieves results 
comparable to surgery for the treatment of appropriately selected ectopic pregnancies and is 
now commonly used (3). The American Society of Reproductive Medicine (ASRM) 
introduced the relative and absolute contraindications to MTX therapy, as indicated in Table 
1 and 2 (4, 5). Lipscomb et al reported that the rate of success with MTX is relatively low in 
cases where serum hCG levels are higher than 5,000 IU/ml (Table 3) (6), however, MTX 
treatment has recently been favored in cost-effectiveness analyses. In this study, we 
reviewed EP cases treated with MTX regardless of high initial-hCG levels (>5,000 IU/ml) 
and evaluated the effectiveness of MTX by comparing them with cases where hCG levels 
were less than 5,000 IU/ml. 
 
1. Embryonic cardiac activity detected by transvaginal ultrasonography 
2. High initial hCG concentration (5,000>mIU/ml) 
3. Ectopic pregnancy >4 cm in size as imaged by transvaginal 
ultrasonography 
4. Refusal to accept blood transfusion  
5. Inability to participate in follow-up 
 
Table 1. Relative contraindication to MTX 
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1. Intrauterine pregnancy 
2. Evidence of immunodeficiency  
3. Moderate to severe anemia, leukopenia or thrombocytopenia 
4. Sensitivity to MTX 
5. Active pulmonary disease 
6. Active peptic ulcer disease 
7. Clinically important hepatic dysfunction 
8. Clinically important renal dysfunction 
9. Breast feeding 
 
 
Table 2. Absolute contraindication to MTX 
 
 
 
Initial serum
hCG level(mIU/ml)
Success
(n=30)
Failure
(n=14)
Success rate 
% 
<1000 118 2 98 
1000-1999 40 3 93 
2000-4999 90 8 92 
5000-9999 39 6 87 
10,000-14,999 18 4 82 ≧15,000 15 7 68 
 
 
Table 3. Initial hCG level and success rate 
2. Materials and method 
We performed MTX treatment in 44 cases, 14 of which were high-hCG EP cases with initial 
serum hCG levels greater than 5,000 IU/ml. In our department, diagnosis of EP was 
confirmed, as shown in Figure 1. After getting informed consent for the possibility of 
additional surgical intervention, we administered MTX IM at a dosage of 50 mg/m2. If a 
decline of more than 15% was not identified between days 4 and 7, an additional  50 mg/m2 
of MTX was administered. Weekly MTX treatment was stopped when hCG levels declined 
to less than 25 IU/ml (Table 4). Alteration to surgical intervention was adopted according to 
the patients’ requirements. 
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Fig. 1. 
 
 
Serum hCG 
(mIU/ml) Ampurally Interstitial Cervical 
<1000 12 - - 
1000-1999 7 - - 
2000-4999 11 - - 
5000-9999 6 2 - 
10000-14999 - - 1 
>15000 1 4 - 
 
 
Table 4. Initial serum hCG and pregnancy site 
3. Results 
Fourteen cases of ectopic pregnancy, with initial hCG levels >5,000 IU/ml were treated with 
MTX. Of those 14 cases, 1 had IVF treatment, 1 undertook ovulation induction, and 12 were 
spontaneous pregnancies. It took 3.85 days from the initial visit to confirm the diagnosis of 
EP, and the average gestational week was 7.31 weeks. Hospitalization days were 13.57 days, 
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and MTX was administered 1.35 times. Implantation sites were 7 ampullary, 6 interstitial, 
and 1 cervical (Table 5). The range of initial hCG was from 5,713 to 92,670 IU/ml, and the 
average was 19619.7 IU/ml. More than two administrations of MTX were necessary in 2 
cases, one of which was a case of persistent EP. In that case, additional dactinomycin was 
given. Laparoscopic surgery was adopted in one case of ampullary pregnancy, where  initial 
hCG was 8952 IU/ml (Table 6). 
In the following, we present one successful case and one difficult case where additional 
Actynomycin D was necessary. 
 
Serum hCG 
(mIU/ml) 
Success
(%)
Multiple dose
Failure 
(%) 
<1000 11(91.6) 2 1(8.4) 
1000-1999 6(85.7) 0 1(14.3) 
2000-4999 7(63.6) 2 4(34.6) 
5000-9999 7(87.5) 2 1(12.5) 
10000-14999 1(100) 0 0(0) 
>15000 5(100) 2 0(0) 
Table 5. Clinical outcomes 
 
 
 Regimen  
Multiple dose Methotrxate 1 mg per kg intramusculrarly, alternate days 
(days 1, 3, 5, 7) +leucovorin 0.1mg per kg intramuscularly, 
alternate days (days 2, 4, 6, 8).  Continue until beta-hCG falls 
>15% in 48h or four doses methtorexate.  If beta-hCG 
concentration not <40% of initial value on day 14.   
Single dose Methotrxate 50 mg per m2 intramusculrarly.  If  beta-hCG is 
not <15% between days 4 and 7, repeat dose.  Up to 4 doses 
can be given if beta-hCG does not decline by 15% every week.   
 
Table 6. Regiment of MTX 
Case I 
In the first case, a patient was referred to our hospital for a suspected right interstitial 
pregnancy. Initial serum hCG was 5979 IU/ml and clinical findings were consistent with the 
criteria for the diagnosis of an interstitial pregnancy. The patient selected MTX treatment 
because of her past history with a left salpingectomy for a right ampullary pregnancy. 
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Therefore, a single dose of MTX was administered. Serum hCG was followed up according to 
routine,  and hCG declined within the normal range after a triple administration (Figure 2).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Time-course of serum hCG level in Case I 
Case II 
In the second case, the diagnosis of a right interstitial pregnancy was confirmed by MRI and 
a and high serum hCG level of 26128 IU/ml. Twice before, the patient experienced ectopic 
pregnancy followed by surgical intervention so, therefore, therefore MTX treatment was 
started. However, her serum hCG level elevated to 172 IU/ml following three 
administrations of MTX following the usual single-dose regiment. Therefore, Actinomycin 
D at a dosage of 12 μg/kg was administered, and an MTX-resistant ectopic pregnancy was 
suspected (Figure 3). Post-treatment was uneventful, and the side effect of Actinomycin D 
and MTX was slight nausea alone.  
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Fig. 3. Time-course of serum hCG level in Case II 
4. Discussion 
The treatment of EP with MTX was established in the late 1980s and has become an 
alternative to surgical intervention. Recently, cost-effectiveness analysis has put a priority 
on the patient’s subsequent fertility, rather than on detection and/or complication rates, as 
previously reported (7-9). Effort should be made to confirm the diagnosis of ectopic 
pregnancy definitively before starting MTX treatment; otherwise, complication rates or costs 
could rise on the contrary. Seror et al reported that MTX treatment appeared to be cost-
effective in EP cases where the preservation of fertility was important (10). About 40% of 
women with ectopic pregnancy are treated medically (11), and 90% of them are successfully 
treated without any surgical intervention at all (12). Medical treatment can be carried out on 
an outpatient basis, thus making MTX cheaper than the cost of surgical treatment. Surgical 
intervention is generally adopted when a high possibility of failure and a prolonged time of 
resolution is predicted. A particularly high serum hCG level or the presence of fetal heart 
movement results in medical treatment (13).  
It is actually difficult to diagnose interstitial pregnancy correctly because of the slight 
difference between cornual implantation and interstitial pregnancy. Cornual implantation is 
usually identified in the upper and lateral uterine cavity, whereas interstitial ectopic 
pregnancy is within the proximal intramural portion of the tube. Therefore, the accurate 
diagnosis of an interstitial pregnancy requires precise ultrasound imaging (14). Two 
regimens are commonly used for the administration of MTX (15) (Table 3). The first contains 
the administration of MTX and leucovorin on alternate days until beta-hCG concentrations 
begin to drop. This regimen has a success rate of 93%. The second regimen involves the 
administration of a single dose of MTX, followed by repeated doses every week if beta-hCG 
concentrations do not fall by 15% within days 4 and 7. It has been reported that at least 13% 
of women require two doses, and 1% need more than two; however, more than 90% of 
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women who need a second administration avoid surgical intervention (12). The initial level 
of hCG is the best prognostic indicator of the need for MTX; however, it is still controversial 
as to what IU should be the cut-point in deciding whether the administration of MTX is 
necessary. Lipscomb et al. reported that 94% of 350 women whose initial hCG was less than 
10,000 IU/ml had success with MTX treatment, therefore suggesting that an initial hCG 
level greater than 10,000 IU/ml was a factor in the failure of the treatment (12). On the other 
hand, Gamzu et al. stated that the cut-point to determine the effectiveness of MTX should be 
lowered to between 2000 mIU/ml and 3000 mIU/ml (16). The hCG incremental rate both 
before and after MTX represents an independent risk factor for subsequent tubal rupture. 
Pre-diagnosis concentrations of hCG which increase at least 66% over 48 hours, followed by 
persistently rising hCG concentrations after treatment with MTX, may lower the threshold 
for surgical intervention (17). 
It is widely accepted that above the discriminatory zone of 1,500 IU/l-2500 IU/l, a normal 
intrauterine pregnancy (IUP) should be visible via TVU. At our clinic, we consider an initial 
hCG greater than 1500 IU/ml and an invisible GS clear indicators of a possible ectopic 
pregnancy, and an elevation of hCG greater than 1.5 times in 48 hours without GS confirms 
the diagnosis. Orivieto et al. reported that single-dose MTX treatment for EP does not have a 
negative effect on ovarian function nor on the outcome of following IVF-ICSI (18). Paul et al.  
reported that when hCG is >4000 IU/ml, the failure rate of MTX treatment is 65% (17). In 
this study, the MTX-failure rate of 14 cases where initial hCG was >5000 IU/ml was 7.1% 
(1/14); however, the failure rate of low hCG cases <5000 IU/ml was 16.6%. In tubal 
pregnancy, EP become less vascularized as it invades the tubal serosa, and tubal rupture is 
likely to occur, compared with that in interstitial pregnancy, before MTX treatment can 
solve the EP. Compared with cases of tubal pregnancy, the difficulty in diagnosing 
interstitial pregnancy is thought to be the reason why hCG levels are higher at the time of 
confirming the diagnosis. However, in our study, 14 cases consisted of 7 ampullary, 6 
interstitial and one cervical pregnancy, indicating that tubal pregnancy does not always 
rupture in high-hCG cases. Therefore, more study is necessary to determine the cut-off for 
MTX treatment.  
Recently the cost-effectiveness of treatment has been considered in attempts to save on 
health insurance costs. Seror reported that, although frequent diagnostic ultrasound is 
necessary, MTX is cost-effective compared with surgical intervention (10). However, 
subsequent pregnancies should be followed with extreme caution, and elective cesarean 
section should be considered as an alternative. 
In conclusion, a serum hCG level greater than 5,000 IU/ml is not necessarily resistant to 
MTX treatment, and interstitial pregnancy is a particularly good candidate for conservative 
treatment, even if initial hCG is higher than 5,000 IU/ml. However, MTX failure and tubal 
rupture was identified irrespective of an initial hCG level of 800 IU/ml in tubal pregnancy. 
Emergent access to surgical intervention must be made available.  As well, the patient’s 
awareness of risk and her availability for admission and surgery are equally important. 
Therefore, preparation for surgical intervention for emergent situations, even after 
conservative treatment is determined, is essential. 
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